Investigation on Predictive Molecular Markers of Efficacy for Front-line Immunochemotherapy in Advanced NSCLC

Inclusion Criteria:

1. Patients who are clinically diagnosed with stage IV NSCLC;
2. Patients who submitted samples for molecular testing using the OncoScreen Plus panel and PD-L1 (22C3) immunohistochemistry test at baseline;
3. Patients with negative results for sensitizing mutations for 6 genes, including EGFR, ALK, ROS1, BRAF, MET exon 14 skipping, and RET;
4. Patients without contraindications for immunotherapy;
5. Patients who are 18 years or older at the time of signing the informed consent form;
6. Patients with life expectancy of at least 12 weeks;
7. Patients with ECOG score of 0 or 1;
8. Patients with adequate organ function defined by the following criteria:

   1. Absolute neutrophil count ≥ 1.5109/L;
   2. Platelets ≥ 90109/L;
   3. Hemoglobin ≥ 9.0g/dL;
   4. Albumin levels ≥2.8 g/L;
   5. Total serum bilirubin ≤ 1.5 the upper limit of normal (ULN); for patients with liver metastases, total bilirubin ≤ 2 ULN;
   6. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 ULN; for patients with liver metastases, ALT and AST ≤ 5ULN;
   7. Serum creatinine ≤ 1.5 ULN;
   8. International normalized ratio (INR) or plasma prothrombin time (PT) ≤1.5ULN.

Exclusion Criteria:

1. Patients with other concurrent tumors;
2. Patients with other concurrent medical conditions that may affect their follow-up and short-term survival;
3. Patients with any history of immunotherapy;
4. Patients with any history of chemotherapy, radiotherapy or other anti-tumor treatments;
5. Patients with heart function classified as New York Heart Association (NYHA) class III or IV;
6. Patients with peripheral nerve disease;
7. Patients with confirmed hearing loss;
8. Patients with other conditions deemed unsuitable for enrollment by the researchers.